cautiou organ growth outlook
downgrad neutral follow merger announc
oppenheimerfund believ merger provid one-tim lift
earn via expens redund could pressur net
flow next five year merger-rel attrit combin
poor perform ivz five largest fund specif
doubling-down us retail/act equiti segment believ
continu see signific flow headwind futur also
estim downsid ivz posit organ growth rate assumpt
flow oppenheim trend deeper neg
territori believ new compani actual organ growth could
closer
key concern merger ivz accret
target assum larg expens cut zero redund come
invest team beta assumpt plu organ growth
posit vs og rate paid
valuat
oppenheimerfund valu vs ad
expens debt year us bull market gross debt
ebitda equiti credit prefer adjust
massmutu could start sell stock two year futur technic pressur
may given massmutu low cost basi avoid tax
oppenheim
im sorri got stock call wrong upgrad stock
thesi stock cheap rel buy-back come
back jemtsep provid lift flow ivz
wouldnt like continu under-perform
concern ivz organ growth rate next five year
accordingli reduc target price
driven lower forecast ivz ep growth cheaper public
market valuat asset manag stock
valuat metric
price month
outperform neutral
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
servic distribut
third-parti distribut servic adv fee
properti offic
gener administr
equiti earn unconsolid affili
realiz unreal gain net
sale busi
incom incom tax mi
adjust net incom tax
total run-rat target
incom tax
synergi post close
invesco aum billion
begin period
net flow institut mmkt fund
apreci beg period aum
institut mmkt powershar qqq
end period
aum invest object billion
net flow institut mmkt fund
price oct rate outperform neutral target price analyst craig
asset manag
ltd independ global invest
manag compani provid rang invest
strategi vehicl retail institut high-net-worth
valuat base multipl
repres premium base case multipl
adjust cash earn estim incorpor bull market
assumpt current annual equiti market
assumpt increas annual organ growth
grey valuat base multipl
repres discount base case multipl
adjust cash earn estim incorpor conserv
market assumpt current annual equiti
market assumpt decreas annual organ
 close
compani mention price
